This study presents a novel approach for anticancer vaccination and drug delivery using cancer cell membrane-coated nanoparticles (CCNPs). The researchers developed CCNPs by coating polymeric nanoparticles with cancer cell membranes, which retain the full array of cancer cell membrane antigens. These CCNPs offer a robust platform for multiple anticancer therapies, including vaccine development and targeted drug delivery. The CCNPs were shown to efficiently deliver tumor-associated antigens to antigen-presenting cells, promoting anticancer immune responses. Additionally, the CCNPs exhibited source cell-specific targeting due to their homotypic binding properties, enabling effective cancer targeting. The CCNPs were synthesized by first isolating cancer cell membranes and then coating them onto poly(lactic-co-glycolic acid) (PLGA) nanoparticle cores. The resulting CCNPs were characterized for their physicochemical properties, including size, zeta potential, and morphology. The CCNPs were found to have a hydrodynamic size of approximately 110 nm and a surface zeta potential similar to that of the cancer cell membranes. Transmission electron microscopy confirmed the formation of a core-shell structure with the cancer cell membrane coating. The CCNPs were also shown to effectively deliver tumor-associated antigens to dendritic cells, leading to their maturation and subsequent activation of T-cells. The CCNPs were found to be highly effective in presenting tumor antigens, as demonstrated by the increased secretion of interferon-gamma (IFNγ) by T-cells. Additionally, the CCNPs exhibited homotypic targeting capabilities, allowing them to bind specifically to cancer cells due to the presence of cancer cell surface antigens. The study highlights the potential of CCNPs as a versatile platform for cancer immunotherapy and drug delivery. The CCNPs can be functionalized with immunological adjuvants to enhance their immunogenicity and can be used for targeted drug delivery by leveraging the homotypic binding properties of cancer cell membranes. The results demonstrate the broad applicability of the cell membrane coating approach for nanoparticle functionalization, which bridges the properties of natural membrane components with those of synthetic nanomaterials. This approach offers a promising avenue for the development of novel, nature-inspired nanotherapeutics with complex antigenic information and surface properties.This study presents a novel approach for anticancer vaccination and drug delivery using cancer cell membrane-coated nanoparticles (CCNPs). The researchers developed CCNPs by coating polymeric nanoparticles with cancer cell membranes, which retain the full array of cancer cell membrane antigens. These CCNPs offer a robust platform for multiple anticancer therapies, including vaccine development and targeted drug delivery. The CCNPs were shown to efficiently deliver tumor-associated antigens to antigen-presenting cells, promoting anticancer immune responses. Additionally, the CCNPs exhibited source cell-specific targeting due to their homotypic binding properties, enabling effective cancer targeting. The CCNPs were synthesized by first isolating cancer cell membranes and then coating them onto poly(lactic-co-glycolic acid) (PLGA) nanoparticle cores. The resulting CCNPs were characterized for their physicochemical properties, including size, zeta potential, and morphology. The CCNPs were found to have a hydrodynamic size of approximately 110 nm and a surface zeta potential similar to that of the cancer cell membranes. Transmission electron microscopy confirmed the formation of a core-shell structure with the cancer cell membrane coating. The CCNPs were also shown to effectively deliver tumor-associated antigens to dendritic cells, leading to their maturation and subsequent activation of T-cells. The CCNPs were found to be highly effective in presenting tumor antigens, as demonstrated by the increased secretion of interferon-gamma (IFNγ) by T-cells. Additionally, the CCNPs exhibited homotypic targeting capabilities, allowing them to bind specifically to cancer cells due to the presence of cancer cell surface antigens. The study highlights the potential of CCNPs as a versatile platform for cancer immunotherapy and drug delivery. The CCNPs can be functionalized with immunological adjuvants to enhance their immunogenicity and can be used for targeted drug delivery by leveraging the homotypic binding properties of cancer cell membranes. The results demonstrate the broad applicability of the cell membrane coating approach for nanoparticle functionalization, which bridges the properties of natural membrane components with those of synthetic nanomaterials. This approach offers a promising avenue for the development of novel, nature-inspired nanotherapeutics with complex antigenic information and surface properties.